The Satellite Symposium, titled ‘Working towards precision medicine approaches for CLL’, provided insights into current therapeutic options for patients with chronic lymphocytic leukemia (CLL), including continuous vs fixed-duration treatments with targeted therapies such as BTK inhibitors (BTKi). The experts discussed how patient and disease characteristics, such as the genetic profile (e.g., del(17p), r\65, S3UX), inform treatment selection and sequencing. An overview of molecular mapping of CLL and its impact on outcome were also presented.

Download the Slide-Kit m)7).